Opinion

Video

Diagnostic Tests for Kidney Cancer

Urologists provide an overview of diagnostic tests for patients with kidney cancer, highlighting lab tests, imaging, and considerations for biopsy.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Medcast series
Oliver Sartor, MD, is featured in this series.
Oliver Sartor, MD, is featured in this series.
1 KOL is featured in this series.
Related Content
Cellular structures show link with survival outcomes in ccRCC
January 2nd 2025

Cellular structures show link with survival outcomes in ccRCC

Hannah Clarke
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
First patient dosed in phase 1 trial of ADI-270 in ccRCC
December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke
Initial data from the trial are expected to be released in the first half of 2025.
Belzutifan nears EU approval for advanced renal cell carcinoma
December 13th 2024

Belzutifan nears EU approval for advanced renal cell carcinoma

Hannah Clarke
A final decision on marketing authorization is anticipated for Q1 of 2025.
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
© 2025 MJH Life Sciences

All rights reserved.